Clinical Guides
Oesophageal Cancer
A clinically focused guide to detecting, staging and coordinating oesophageal cancer care in India, integrating histology-specific treatment, nutrition, obstruction safety and explicit limits on foreign guideline transfer.
MedNext Academy | 14 min read
Oesophageal Cancer
A clinically focused guide to detecting, staging and coordinating oesophageal cancer care in India, integrating histology-specific treatment, nutrition, obstruction safety and explicit limits on foreign guideline transfer.
Summary
Oesophageal cancer is a malignant tumour of the muscular conduit between pharynx and stomach. Most cases are squamous cell carcinoma or adenocarcinoma, two diseases with different epidemiology, typical location and treatment considerations. Squamous carcinoma can arise throughout the oesophagus and remains the predominant global histology; adenocarcinoma usually affects the distal oesophagus or gastro-oesophageal junction and is associated with Barrett metaplasia. Junctional tumours require careful anatomical classification because an apparent cardia mass and a distal oesophageal primary may follow different staging or protocol pathways. Histology and epicentre must therefore be documented, not assumed from symptoms.
Progressive dysphagia, often first for solids and later liquids, is the classic alarm symptom. Weight loss, odynophagia, regurgitation, aspiration, iron-deficiency anaemia, haematemesis, chest or back pain and hoarseness can occur. Symptoms commonly appear after luminal narrowing, so a normal general examination does not exclude advanced disease. Diagnosis requires upper gastrointestinal endoscopy with adequate biopsy. CT defines anatomy and metastases; PET-CT and endoscopic ultrasound are selected when their findings will change radical management.
Treatment is stage-, histology- and fitness-specific. Very early mucosal disease may be managed endoscopically in expert centres. Other potentially curable disease may require oesophagectomy, definitive chemoradiotherapy, perioperative chemotherapy or preoperative chemoradiotherapy. Advanced disease needs biomarker-informed systemic treatment and active palliation of dysphagia, pain and malnutrition. Nutritional support starts during assessment, not after treatment failure. Current guidelines describes a UK pathway and NCI PDQ summarises predominantly international evidence; neither substitutes for an Indian tumour board, locally approved medicines or available surgical and radiation expertise. This draft has been reviewed by the MedNext Clinical Team and reviewed.
How Common Is It?
The IARC Global Cancer Observatory India fact sheet for GLOBOCAN 2024 places oesophageal cancer among important causes of cancer incidence and death in India. Its national figures are modelled estimates, created from available registry rates, population data and mortality modelling rather than a name-by-name national count. The fact sheet separates oesophagus from stomach and other upper-aerodigestive sites. Reports should retain that distinction and cite the data version; combining junctional, gastric-cardia and oesophageal counts from incompatible datasets creates false precision.
India has substantial geographical and sex variation. Squamous carcinoma is strongly influenced by tobacco and alcohol patterns and may also vary with diet, thermal injury exposures, socioeconomic conditions and regional risk environments. Adenocarcinoma has a different pattern linked to Barrett oesophagus, chronic reflux and metabolic factors. The balance between histologies in a Western series should not be projected onto an Indian population without local pathology data. Registry coverage, access to endoscopy and how a junctional tumour is coded also affect apparent incidence.
Incidence describes new diagnoses, mortality describes deaths and prevalence includes people living after diagnosis; they cannot be substituted for one another. A high mortality-to-incidence relationship at population level may reflect late presentation, aggressive biology, comorbidity and unequal access, but it does not calculate an individual's survival. For a patient, histology, anatomical site, TNM stage, response to multimodality treatment, nutrition, performance status and treatment completion matter more. Clinically, any dysphagia warrants urgent evaluation regardless of whether the patient's age, sex or region appears statistically typical.
Risk Factors
Risk assessment begins by separating the major histologies. Tobacco and alcohol are established risk factors for oesophageal squamous cell carcinoma, and combined exposure can multiply harm. In India, ask about cigarettes, bidis and smokeless products rather than recording a binary smoking box. Dietary insufficiency, very hot beverages, chronic mucosal injury and certain environmental exposures have been associated with squamous carcinoma in some populations, but association strength varies and individual causation should not be claimed. Previous head-and-neck squamous cancer raises concern for a second upper-aerodigestive primary. Achalasia and past corrosive injury are uncommon but clinically relevant long-term risk settings.
Distal oesophageal adenocarcinoma has a different pathway. Chronic gastro-oesophageal reflux can lead to Barrett metaplasia, and Barrett oesophagus increases adenocarcinoma risk. Central adiposity, male sex and smoking are associated factors. Most people with reflux never develop cancer, and most dyspepsia does not require cancer labelling; alarm symptoms determine urgent investigation. A known Barrett segment requires surveillance according to an adopted specialist protocol, but surveillance does not protect against every interval cancer.
Risk history should also predict treatment tolerance. Document unintentional weight loss, sarcopenia, dehydration, aspiration, dental health, cardiopulmonary disease, renal and hepatic function, neuropathy, hearing, prior thoracic radiotherapy, frailty and medicines. Ask who can support feeding, travel and recovery after a major resection. Risk reduction includes stopping tobacco, moderating alcohol, treating clinically indicated reflux and maintaining healthy weight, but no supplement or acid-suppressing medicine guarantees prevention. New progressive dysphagia must never be attributed to a known risk condition such as reflux without endoscopic assessment.
Diagnosis
History
Characterise dysphagia by onset, progression and consistency: difficulty first with solids and later liquids suggests a narrowing lesion, whereas intermittent symptoms for both from the outset can suggest motility disease, but patterns overlap. Ask about odynophagia, food impaction, regurgitation, aspiration, cough after swallowing, haematemesis, melaena, anaemia symptoms, chest or interscapular pain, hoarseness, weight loss and reduced intake. Record reflux and Barrett history, tobacco and alcohol, corrosive injury, achalasia, previous upper-aerodigestive malignancy, treatment, comorbidity and performance status. Establish whether the patient can swallow fluids and saliva now.
Examination
Assess airway, hydration, weight, muscle loss and functional reserve. Look for pallor, supraclavicular or cervical nodes, hepatomegaly, ascites, pleural signs and evidence of aspiration. Hoarseness can indicate recurrent-laryngeal nerve involvement; stridor or inability to handle secretions is an emergency. Examine the oral cavity and neck for a synchronous primary where risk is high. A normal abdominal and chest examination does not exclude oesophageal cancer, and severity of dysphagia is not a reliable anatomical stage.
Investigations
Urgent upper gastrointestinal endoscopy maps the lesion and obtains multiple representative biopsies. Pathology must distinguish squamous carcinoma, adenocarcinoma and other tumours; junctional epicentre and HER2 or other biomarker needs are discussed by the MDT. Whole-body or chest-abdominal CT is the staging foundation. Current guidelines recommends FDG PET-CT for oesophageal or junctional tumours suitable for radical treatment except T1a, and endoscopic ultrasound only when it will guide management. Endoscopic mucosal resection can provide accurate staging for suspected T1N0 disease. Bronchoscopy is considered for tumours near the tracheobronchial tree, and laparoscopy only for selected junctional cases when it changes the plan. Nutritional and anaesthetic assessments run in parallel.
Differential Diagnosis
Benign mechanical obstruction includes peptic stricture, Schatzki ring, postoperative or radiation stricture and a benign tumour. Eosinophilic oesophagitis may cause recurrent food bolus obstruction, particularly in a younger patient, but requires endoscopic biopsy rather than inference from atopy. External compression from mediastinal lymphadenopathy, thyroid enlargement, vascular abnormalities or another thoracic mass can mimic an intraluminal lesion. A retained foreign body is usually acute. Any progressive or unexplained dysphagia still needs endoscopy even when reflux or a prior stricture seems plausible.
Motility disorders include achalasia, oesophagogastric junction outflow obstruction, spasm and systemic-sclerosis-associated dysmotility. Achalasia can create a dilated oesophagus and regurgitation; pseudoachalasia from a junctional cancer must be excluded, especially with rapid weight loss, short symptom duration or difficulty passing the endoscope. Oropharyngeal dysphagia typically causes difficulty initiating a swallow, coughing or nasal regurgitation and directs assessment toward neurological, muscular or pharyngeal disease. Symptom localisation is imperfect, so a patient pointing to the neck may still have a distal obstruction.
Inflammatory and infectious causes include reflux oesophagitis, pill injury, caustic injury and Candida, herpes or cytomegalovirus oesophagitis in susceptible patients. These more often cause odynophagia but can coexist with malignancy. Gastric-cardia cancer can extend proximally; classification depends on the tumour's epicentre, not the label used on an initial referral. Lymphoma, melanoma, gastrointestinal stromal tumour and metastasis are uncommon histological alternatives. The correct response to clinical-pathological discordance is deeper review, repeat targeted sampling or multidisciplinary radiology-pathology correlation, not repeated empirical acid suppression.
Management
All confirmed cases should be discussed in an oesophago-gastric multidisciplinary meeting, with localised non-metastatic disease reviewed by a specialist team and curative resection undertaken in a specialist unit. Planning combines anatomical site, squamous versus adenocarcinoma histology, TNM stage, resectability, physiological fitness, nutritional status and patient preference. Very early mucosal lesions may be staged and treated by endoscopic resection, sometimes with additional ablation in an expert Barrett programme. Endoscopic therapy is not appropriate for disease with substantial submucosal or nodal risk.
For resectable non-metastatic squamous carcinoma, current guidelines offers a choice between radical chemoradiotherapy and chemoradiotherapy followed by surgery in appropriate patients. Localised oesophageal or junctional adenocarcinoma proceeding to surgery commonly receives preoperative or perioperative systemic treatment, or preoperative chemoradiotherapy, according to the MDT protocol. Oesophagectomy may be open, minimally invasive or hybrid; approach matters less than specialist volume, oncological quality and management of pulmonary, anastomotic and nutritional complications. Response, pathology and postoperative fitness determine further treatment.
When cure is not feasible, systemic therapy is chosen by histology, biomarkers, prior exposure, organ function and current approvals. Dysphagia may be palliated with a self-expanding stent or radiotherapy, but timing matters: stenting can complicate subsequent radical treatment and is not a casual bridge before staging. Feeding access should be planned with the definitive team because route can affect future reconstruction. Early dietetic and palliative input address intake, pain and goals alongside anticancer therapy. current guidelines' service structure and funded drugs differ from Indian settings; the local tumour board must adapt evidence to surgical volume, radiation access, pathology, affordability and patient travel.
Prescribing Information
Oesophageal-cancer medicines are protocol treatments, not standalone prescriptions. Cytotoxic combinations may accompany radiotherapy, precede surgery, surround surgery or treat metastatic disease. Selection depends on squamous versus adenocarcinoma histology, renal and hepatic function, neuropathy, hearing, cardiac reserve, performance status, nutritional state and previous exposure. Fluoropyrimidines can cause diarrhoea, mucositis, cytopenias and cardiac toxicity; platinum agents can cause renal injury, electrolyte loss, neuropathy, ototoxicity and severe nausea. Taxanes can cause neuropathy, hypersensitivity and myelosuppression. Exact doses, infusion schedules, hydration and dose modifications require the treating oncology protocol.
Advanced adenocarcinoma should undergo relevant biomarker evaluation; current guidelines specifically recommends HER2 testing for advanced oesophago-gastric adenocarcinoma. Depending on histology, current approvals and tumour biomarkers, targeted or immune checkpoint treatments may be combined with chemotherapy or used later. Immune-related colitis, pneumonitis, hepatitis, nephritis, endocrinopathy, myocarditis and neurological toxicity can occur during or after therapy. New diarrhoea, dyspnoea, jaundice, severe fatigue, chest pain or confusion needs urgent oncology advice rather than routine symptomatic treatment.
Supportive prescribing includes guideline-based antiemetics, analgesia, bowel care, acid suppression when indicated, thrombosis assessment and treatment of documented infection. Fever after systemic therapy is an emergency because neutropenic sepsis can progress rapidly. Tablets are unsafe if swallowing is unreliable; do not crush modified-release or hazardous anticancer medicines without pharmacy review. Enteral formulas and electrolytes require monitoring during refeeding in a severely malnourished person. Stent pain, reflux or migration needs procedural review. Indian teams must confirm drug approval, biosimilar or formulation quality, funding, interaction checks and access to toxicity monitoring before translating an international regimen.
When to Refer
Dysphagia itself is sufficient for a suspected-cancer pathway referral in current guidelines; do not wait for weight loss or anaemia. Also refer urgently when a person aged 55 or over has weight loss with upper abdominal pain, reflux or dyspepsia. These are UK thresholds that organise a specific health system, not a ceiling on Indian clinical judgement. Any progressive dysphagia, food sticking, recurrent impaction, unexplained odynophagia or concerning weight loss merits prompt upper gastrointestinal endoscopy through the locally available pathway. Improvement with a proton-pump inhibitor does not exclude a structural lesion.
Specialist escalation is needed for haematemesis, melaena, iron-deficiency anaemia, persistent vomiting, aspiration, new hoarseness, supraclavicular lymphadenopathy or imaging suggesting oesophageal wall thickening. Refer a known Barrett patient with dysplasia or a new alarm symptom to an expert endoscopy service. A biopsy-confirmed cancer should go directly to an oesophago-gastric MDT while CT, nutrition and fitness work proceed; serial referrals between general clinics waste nutritional and staging time. Early dietetic referral is appropriate at diagnosis, even before treatment modality is chosen.
Send immediately to emergency care for inability to swallow saliva, complete food-bolus obstruction, respiratory distress, stridor, significant aspiration, major haematemesis, syncope, shock or perforation features such as severe chest pain with systemic toxicity. During treatment, fever, rigors, dehydration, uncontrolled vomiting, reduced urine output, severe diarrhoea or new breathlessness needs same-day oncology assessment. After oesophagectomy, tachycardia, hypoxia, fever, chest pain or sepsis can signal an anastomotic or pulmonary complication and requires urgent surgical-team review.
Red Flags
Progressive dysphagia is the principal cancer red flag, especially when solid-food difficulty advances to liquids, but atypical patterns do not confer safety. Unintentional weight loss, odynophagia, recurrent food impaction, regurgitation of retained food, aspiration, haematemesis, melaena, unexplained iron-deficiency anaemia, persistent vomiting, chest or back pain, hoarseness and a left supraclavicular node increase concern. New symptoms in a person with Barrett oesophagus, achalasia, previous corrosive stricture or head-and-neck cancer require a low threshold for endoscopy. Age modifies probability but does not invalidate a serious symptom in a younger adult.
Emergency red flags are inability to manage saliva, acute complete obstruction, stridor, respiratory compromise, massive bleeding, syncope, haemodynamic instability and suspected perforation. Severe dehydration or malnutrition can also require admission even without dramatic vital-sign changes. During chemotherapy or chemoradiotherapy, fever, rigors, confusion, hypotension, reduced urine output, severe mucositis, uncontrolled diarrhoea or worsening dyspnoea may represent sepsis or treatment toxicity. After stent placement, severe chest pain, bleeding, respiratory symptoms or abrupt recurrent obstruction needs urgent procedural review.
After oesophagectomy, persistent tachycardia, fever, hypoxia, new atrial arrhythmia, chest pain, cervical wound discharge or sepsis must raise concern for anastomotic leak, pulmonary complication or infection. Later, recurrent dysphagia may reflect anastomotic stricture but cancer recurrence must be excluded. A normal examination, temporary improvement on acid suppression or an old benign endoscopy should not reassure against a new progressive pattern. Every non-urgent plan needs a documented maximum wait, nutritional safety check and instructions for what should trigger earlier escalation.
Indian Clinical Context
India's challenge is not only recognising dysphagia but moving a patient rapidly from symptom to endoscopy, histology, staging and a feasible multimodality plan. Endoscopy and specialist oesophago-gastric surgery are concentrated unevenly, while repeated travel, lost wages, nutritional decline and the cost of imaging can interrupt the pathway. A primary clinician can reduce delay by treating dysphagia as an alarm symptom, documenting current oral intake and weight, arranging the correct referral destination, and avoiding prolonged empirical reflux therapy. Referral should state whether the patient tolerates liquids and whether aspiration or complete obstruction is developing.
Risk histories should fit local exposure: bidis and other smoking, smokeless tobacco, alcohol, dietary pattern, corrosive ingestion and regional residence. However, an exposure history does not replace endoscopy. Squamous carcinoma predominance in many Indian settings means Western adenocarcinoma-heavy data cannot simply determine service planning. The current IARC India fact sheet provides modelled national context, but state registry and hospital audit data are needed for local capacity, histological mix and stage at presentation.
Treatment must be realistic without becoming second-rate. Referral to a higher-volume surgical or radiation centre may improve technical options, yet distance and follow-up feasibility must be addressed before a complex plan. Nutrition support, pathology quality, biomarker turnaround, blood products, critical care, toxicity monitoring and palliative procedures all influence safe delivery. current guidelines assumes defined UK specialist networks and commissioning; NCI PDQ is an evidence review rather than an Indian guideline. Indian tumour boards should document adaptations based on national approvals, local expertise, affordability and patient goals. A palliative plan should still provide active relief of dysphagia, nutrition, pain and psychosocial distress.
NMC Competency Mapping
The 2024 National Medical Commission curriculum maps oesophageal cancer across pathology and surgery. PA23.2 requires learners to describe the aetiology, pathogenesis, pathology, microbiology, clinical and microscopic features of carcinoma oesophagus. SU28.5 covers applied anatomy and physiology of the oesophagus, while SU28.6 addresses clinical features, investigations and principles of management of benign and malignant oesophageal disorders. EN4.45 adds clinical features, investigations and management principles for diseases of the oesophagus. Together they support integrated reasoning from anatomy and swallowing physiology through pathology, staging and treatment.
A competent undergraduate should distinguish squamous carcinoma from adenocarcinoma, recognise progressive dysphagia and nutritional compromise, and separate oropharyngeal transfer difficulty from oesophageal obstruction. They should explain why endoscopy with biopsy establishes diagnosis and why CT, PET-CT and endoscopic ultrasound answer different staging questions. They should understand the significance of longitudinal lymphatics, local invasion into airway or mediastinal structures, regional nodes and distant metastases. Case presentation should include anatomical level, junctional relationship, histology, stage evidence, nutrition and fitness rather than merely naming the cancer.
Management outcomes include principles of endoscopic therapy for selected early lesions, oesophagectomy, perioperative therapy, definitive chemoradiotherapy, biomarker-directed advanced treatment, stenting and nutrition. The learner must not convert these principles into unsupervised prescribing. Useful assessments include an alarm-symptom referral vignette, interpretation of endoscopic and CT descriptions, pathology comparison and an MDT plan. Communication includes explaining uncertainty, discussing feeding and treatment burden sensitively and escalating complete obstruction. The curriculum does not endorse one foreign regimen or screening programme; supervised local protocols remain authoritative.
Key Exam Pearls for NEET PG
Two histologies dominate. Squamous cell carcinoma may occur at any level and is strongly associated with tobacco and alcohol; adenocarcinoma usually involves the distal oesophagus or junction and is linked to Barrett metaplasia and chronic reflux. The oesophagus has rich longitudinal submucosal lymphatics, helping explain non-contiguous nodal spread. Tumour level is described from the incisors at endoscopy. Progressive dysphagia for solids followed by liquids suggests mechanical obstruction, while difficulty initiating a swallow points toward an oropharyngeal process; these are patterns, not absolute rules.
Diagnosis requires endoscopic biopsy. CT assesses local and distant disease, FDG PET-CT helps detect occult metastases in radical candidates, and endoscopic ultrasound is used when additional T or nodal detail will change treatment. current guidelines does not recommend EUS simply to distinguish T2 from T3 in every case. Suspected T1N0 disease may undergo endoscopic mucosal resection for staging because biopsy and imaging can underestimate depth. HER2 testing is relevant to advanced oesophago-gastric adenocarcinoma, not squamous disease by default.
Early mucosal disease can be endoscopically treatable; deeper or nodal disease usually requires multimodality assessment. Definitive chemoradiotherapy is an important curative option for squamous carcinoma, while adenocarcinoma proceeding to surgery commonly receives preoperative or perioperative treatment. Dysphagia palliation can use self-expanding stents, but stents are not automatically appropriate before a radical plan is settled. Nutrition is part of cancer treatment. In an examination vignette, complete obstruction, aspiration, major bleeding or perforation features take priority over elective staging.
Frequently Asked Questions
Does difficulty swallowing always mean oesophageal cancer?
No. Reflux stricture, rings, eosinophilic oesophagitis, achalasia and neurological swallowing disorders are among the alternatives. However, dysphagia is an alarm symptom because symptoms alone cannot reliably distinguish them. Progressive or unexplained dysphagia needs prompt endoscopic assessment rather than repeated empirical reflux treatment.
Why are both PET-CT and endoscopic ultrasound sometimes considered after CT?
They answer different questions. PET-CT can reveal distant metabolically active disease that changes curative intent, while endoscopic ultrasound can add local-depth or regional-node information when that affects treatment. Neither is automatic for every tumour. Current guidelines recommends selecting EUS only when it will guide management and PET-CT for appropriate radical candidates.
Will every patient with oesophageal cancer require oesophagectomy?
No. Selected very early lesions may be removed endoscopically, some squamous cancers can be treated with definitive chemoradiotherapy, and metastatic or medically inoperable disease may need systemic or palliative care. Surgery is a specialist option based on histology, site, stage, fitness and preference, usually within a multimodality plan.
Is inserting an oesophageal stent always the first treatment for dysphagia?
No. A stent can rapidly palliate malignant obstruction when cure is not feasible, but it can cause pain, reflux, migration, bleeding or fistula and may complicate a future radical pathway. The MDT should define treatment intent and feeding strategy first unless emergency obstruction demands immediate intervention. Other palliative approaches may be more suitable.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic